1 citations
,
January 2025 in “Annals of Dermatology” Baricitinib is effective and safe for treating alopecia areata in Korea.
5 citations
,
January 2018 in “Skin Pharmacology and Physiology” Curcuma aeruginosa extract lotion significantly reduces underarm hair growth.
February 2026 in “Journal of Nanobiotechnology” A new treatment using a special gel with miR-665 reduces inflammation and helps hair regrow in alopecia areata.
9 citations
,
April 2021 in “Expert opinion on pharmacotherapy” Clascoterone is a new, effective, and safe acne treatment without systemic side effects.
49 citations
,
February 2022 in “Drug Design Development and Therapy” Ritlecitinib shows promise for hair regrowth in alopecia areata patients.
4 citations
,
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib was effective in regrowing hair in patients with different levels of alopecia areata severity.
January 2022 in “Dermatology Review” EGFR inhibitors can cause unusual localized hair growth.
4 citations
,
May 2025 in “Dermatology and Therapy” Baricitinib effectively improves symptoms of atopic dermatitis and alopecia areata with few side effects.
30 citations
,
August 2009 in “Journal of the American Academy of Dermatology” Bimatoprost is safe but not effective for severe eyelash loss from alopecia areata, possibly helping those with less loss.
1 citations
,
January 2013 in “MedChemComm” PF-05314882 selectively activates androgen receptors without much effect on prostate and may help in prostate cancer treatment and hair loss prevention.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Baricitinib is widely used for several conditions, especially COVID-19, but its safety and effectiveness are still being evaluated.
January 2023 in “Cutaneous and Ocular Toxicology” 2 citations
,
May 2020 in “JAAD case reports” Ruxolitinib can cause a delayed skin reaction on the nose.
65 citations
,
April 2002 in “Journal of Alternative and Complementary Medicine” Plant extracts effectively reduce hair loss and increase growth, offering a safe alternative treatment.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for hair loss and prostate issues without hormonal side effects.
November 2022 in “bioRxiv (Cold Spring Harbor Laboratory)” Prostaglandin E2 helps prevent hair loss from radiotherapy by protecting hair cells.
1 citations
,
June 2008 in “The Journal of Urology” Dihydrotestosterone gel before hypospadias surgery led to less scarring but raised concerns about potential psychological effects and skin changes.
November 2025 in “Journal of Medicinal Chemistry” Topical PROTACs show promise for treating skin conditions but need better stability and delivery methods.
April 2024 in “Clinical and experimental dermatology” Tofacitinib is effective for severe alopecia areata, similar to oral betamethasone.
1 citations
,
June 2007 in “Journal of Clinical Oncology” Weekly bicalutamide is safe and effective, with 50 mg/week recommended.
6 citations
,
October 2015 in “Clinical Case Reports” A woman with acromegaly experienced severe hair loss from a drug called Lanreotide Autogel, which improved after stopping the treatment.
5 citations
,
August 2024 in “Frontiers in Immunology” Upadacitinib effectively treats psoriasiform eczema and some related conditions.
December 2023 in “Journal of Cosmetic Dermatology” Baricitinib effectively and safely improves hair growth in patients with severe alopecia areata.
June 2025 in “British Journal of Dermatology” Ruxolitinib helped a woman with a genetic mutation regrow her hair and improved her health.
75 citations
,
August 2005 in “Expert Opinion on Pharmacotherapy” Acitretin is effective for certain types of psoriasis, safe for long-term use, and often combined with other treatments.
September 2025 in “Intisari Sains Medis” The combination therapy improved severe alopecia areata in a patient after 14 days.
17 citations
,
January 2019 in “Dermatologic Therapy” Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.
December 2025 in “Clinical & Experimental Dermatology and Therapies” Cosmerna ARI effectively reduces hair loss and increases hair density in Europeans with androgenetic alopecia.
2 citations
,
March 2013 in “Phytotherapy Research” Ascorbigen increases hair cell growth in a lab setting but does not prevent hair loss from chemotherapy in mice.
August 2023 in “European journal of dermatology/EJD. European journal of dermatology” Combining topical delgocitinib with a 308-nm excimer laser can effectively treat severe alopecia areata and vitiligo.